MEI Pharma(MEIP) - 2019 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended the fiscal year with $79.8 million in cash and equivalents, with no outstanding debt, compared to $39.4 million cash used in operations, an increase from $21 million the previous year [10][11] - Research and development expenses rose to $32.3 million from $17 million, primarily due to increased activities in clinical programs [10] - General and administrative expenses increased to $14.6 million from $9.8 million, attributed to professional services and share-based compensation [11] - Revenues for the year were $4.9 million, up from $1.6 million, driven by higher research and development activities [11] - The net loss was $16.8 million or $0.24 per share, an improvement from a net loss of $40.1 million or $0.97 per share in the previous year [12] Business Line Data and Key Metrics Changes - The company is advancing its pipeline of four clinical-stage oncology candidates, focusing on ME-401, a PI3 delta inhibitor for B-cell malignancies, and voruciclib, a CDK inhibitor [15][44] - ME-401 is undergoing a Phase 2 clinical trial for follicular lymphoma, with plans for accelerated approval based on the results [28] - Voruciclib is being evaluated in a Phase I clinical trial for safety and efficacy in B-cell malignancies and AML [49] Market Data and Key Metrics Changes - The addressable market for B-cell malignancies is estimated at approximately 50,000 patients in the United States [42] - The company is exploring various combination therapies to enhance treatment efficacy in B-cell malignancies, including partnerships with BeiGene and Kyowa Kirin [36][38] Company Strategy and Development Direction - The company aims to build a strong foundation to deliver value to stakeholders while advancing its clinical pipeline [15] - There is a focus on developing ME-401 as a next-generation PI3K delta inhibitor, with plans for combination therapies to address unmet medical needs in B-cell malignancies [39][41] - The company is considering both independent commercialization and strategic partnerships to maximize the potential of its candidates [42][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to continue advancing clinical candidates and building shareholder value [59] - The company is preparing for potential regulatory submissions and is focused on ensuring the safety and efficacy of its therapies [76][91] Other Important Information - The company has received breakthrough designation from the FDA for pracinostat in AML treatment and is evaluating its potential in high-risk MDS [57] - The company is actively pursuing collaborations to enhance the development of its candidates and is open to exploring various therapeutic combinations [39][115] Q&A Session Summary Question: Thoughts on zanubrutinib combinations and dosing - Management confirmed that the initial dosing for the combination study is based on safety profiles and that they are not currently focusing on CLL due to existing strong treatments [63][65] Question: Update on ME-401 and patient enrollment - Management indicated that there would not be significant updates at the upcoming ASH meeting, as they are focusing on the registration study [75] Question: Enrollment in Phase 2 registration study - Management stated that they will not provide regular enrollment updates but are on track to meet their goals for patient enrollment [85][86] Question: Future development strategies for pracinostat - Management is considering various strategies for EU registration and is planning confirmatory studies based on ongoing discussions with advisors [91][92] Question: Cash run rate and partnership aspirations - Management clarified that the rationale for partnerships is to optimize development resources rather than solely to extend cash run rates [119][121]